Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2017

View Archived Issues

ILiAD presents promising data from phase Ib trial of BPZE-1 pertussis vaccine

ViraCyte receives grants from NIH and FDA to advance T-cell immunotherapies

AVN-492 shows promising preclinical profile in several behavioral rodent models

Istodax approved in Japan for peripheral T-cell lymphoma

Dual BH3 mimetic targeting of Bcl-2 and Mcl-1 may be effective for treating acute myeloid leukemia

German grant supports cancer immunotherapy program at Evotec

Phase II study of BGB-A317 in urothelial cancer begins in China

Array BioPharma submits NDAs in U.S. for combination of binimetinib and encorafenib

CIRM grant supports SanBio's phase IIb trial of SB-623 to treat chronic stroke

FDA places clinical hold on trials of Keytruda in multiple myeloma

Cynata Therapeutics receives advice from FDA on Cymerus development plans

Celgene and BeiGene establish strategic immuno-oncology collaboration

Promising preclinical data for the novel CKI-alpha activator SSTC-3

GlaxoSmithKline describes novel 5'-nucleotidase inhibitors

Recro Pharma acquires neuromuscular blocking agents and reversal agent from Cornell University

Gilead investigates entospletinib in childhood B-cell acute lymphoblastic leukemia

Konica Minolta to acquire Ambry Genetics

Induced neural stem cell therapy shows promise for treating Huntington's disease

Innocare initiates phase I trial of ICP-022

Taconic and Pharmatest collaborate on human immune system model for bone metastasis

MDxHealth announces U.S. launch of AssureMDx for Bladder Cancer test

NIH grant supports Scripps' development of screening for childhood brain disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...